Deanett Evans, APRN
Adult Health · Waterbury, CTNPI 1104571595
Payments from drug & device makers
Across 695 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi$1K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$951
- plus $5K from 32 others
What the payments were for
- Food & beverage$13,27797%
- Education$3993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $2,213 |
| GSK | 67 | $1,450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 92 | $1,417 |
| Sanofi | 63 | $1,349 |
| Amgen | 73 | $1,296 |
| Regeneron Healthcare Solutions, Inc. | 46 | $951 |
| Boehringer Ingelheim | 40 | $719 |
| Baxter Healthcare | 37 | $516 |
| Mylan Specialty L.p. | 26 | $452 |
| Novartis | 32 | $368 |
| Grifols USA, LLC | 20 | $362 |
| Viatris Specialty LLC | 16 | $361 |
| Electromed, Inc. | 18 | $314 |
| Verona Pharma, Inc. | 14 | $305 |
| Genentech USA, Inc. | 18 | $298 |
| Actelion Pharmaceuticals US, Inc. | 4 | $181 |
| Mallinckrodt Hospital Products Inc. | 3 | $147 |
| Optinose US, Inc. | 6 | $140 |
| Philips North America LLC | 5 | $111 |
| Covis Pharma GmbH | 5 | $87 |
| Pfizer | 4 | $83 |
| Vifor Pharma, Inc. | 3 | $73 |
| AbbVie | 3 | $67 |
| Phadia US Inc. | 4 | $63 |
| Paratek Pharmaceuticals, Inc. | 3 | $58 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Insmed, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| CSL Behring | 1 | $27 |
| Merck | 1 | $25 |
| Pulmonx Corporation | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| 3b Medical, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,676 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 221 | $260,773 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $137,921 |
| XolairOmalizumab | 12 | $65,040 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $42,817 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $25,219 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $23,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $22,022 |
| Spiriva RespimatTiotropium Bromide | 15 | $21,735 |
| Spiriva HandihalerTiotropium Bromide | 13 | $18,602 |
| DuleraMometasone/Formoterol | 22 | $10,723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 300 | $9,671 |
| Arnuity ElliptaFluticasone Furoate | 30 | $8,136 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $7,654 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $6,874 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 18 | $6,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,450 | $449,647524 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $719 | $46,95538 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $2,213 | $45,35478 claims |
| MerckDulera | $25 | $10,72322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in Waterbury
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.